Objective The burden of candidemia is shifting from intensive care units (ICU) to non-ICU settings. This study aimed to define the differences in epidemiology and predictors of death between ICU-acquired candidemia (ICUAC) and non-ICUAC. Methods We conducted a retrospective study of 80 patients with ICUAC and 147 patients with non-IUCAC at five hospitals. Results The distribution of Candida species and resistance to antifungal agents did not differ between the ICUAC and non-ICUAC groups. ICUAC patients received more echinocandins and less triazoles, as well as more adequate antifungal therapy than non-ICUAC patients (all p<0.05). ICUAC patients had a significantly higher average acute physiology and chronic health evaluation (APACHE) II score (21.0±7.9 vs. 17.8±8.6; p<0.01), Sequential Organ Failure Assessment score (9.2±5.5 vs. 7.4±3.9; p<0.05) and day-90 mortality rate (52.5% vs. 36.7%; p<0.05) when compared to non-ICUAC patients. Using a multivariate logistic analysis, adequate antifungal therapy was found to be the only protective factor for death in both groups. Respiratory failure supported with invasive mechanical ventilation, renal failure supported with replacement therapy and an APACHE II score ! 20 were independent predictors of death in ICUAC patients, while age ! 60 years, concurrent bacteremia and APACHE II score ! 20 were independent predictors of death in non-ICUAC patients.
Introduction
Candidemia has emerged as an important nosocomial infection associated with significant morbidity and mortality (1, 2) . It is the fourth most common nosocomial bloodstream infection in the United States and the seventh in Europe (3, 4) . In intensive care units (ICUs), candidemia is a serious problem, and an estimated 33% to 55% of all episodes occur in ICUs (5, 6) . However, the incidence of candidemia has increased over the last decade in non-ICU populations, and the burden of candidemia is shifting from ICUs to general hospital wards (7) (8) (9) . A number of studies from different regions have provided endemic epidemiology data regarding candidemia in ICU populations or other atrisk populations (10) (11) (12) (13) (14) (15) , but comparisons between ICUacquired candidemia (ICUAC) and non-ICUAC in a single region remain scarce.
The predictors of death in patients with candidemia are important for the implementation of early intervention. Re-cent studies have disclosed that various risk factors, including an ICU stay, older age, a higher acute physiology and chronic health evaluation (APACHE) II score, neutropenia, corticosteroid therapy (16) (17) (18) and inadequate or lack of initial antifungal treatment (18, 19) , are factors associated with candidemia-related death. However, it is unknown whether these risk factors independently predict poor outcomes both in the patients with ICUAC and patients with non-ICUAC.
In this study, we retrospectively examined differences in the epidemiology and risk factors for death in patients with ICUAC and non-ICUAC at multiple centers in a city in China. We aimed to provide information for ICU and non-ICU physicians to help direct anti-Candida therapy and improve the prognosis of candidemia.
Materials and Methods

Study design and patient selection
We performed a multi-center retrospective study of candidemia during hospital admission in five tri-service general hospitals in Jinan, China: Qilu Hospital of Shandong University (2,000 beds), Jinan Military General Hospital (2,000 beds), Qianfoshan Hospital affiliated with Shandong University (1,500 beds), Jinan Center Hospital affiliated with Shandong University (1,000 beds) and Shandong Provincial Hospital (Jinan, 2,000 beds). Data on patients admitted from January 2008 to June 2010 were reviewed. We included patients older than 16 years who had ICUAC or non-ICUAC. Candidemia was defined as at least one positive blood culture for Candida species in patients hospitalized for more than 48 hours with signs or symptoms of infection. ICUAC represented candidemia acquired more than 48 hours after ICU admission and non-ICUAC candidemia represented candidemia acquired more than 48 hours after admission to non-ICU settings. All episodes of candidemia were identified via the laboratory computer system. Post-discharge survival data were obtained from the Follow-up Departments of the hospitals. For patients with multiple candidemic episodes, only the first episode was included. Patients with candidemia caused simultaneously by different species of Candida were excluded. The study was approved by the Ethics Committee of Qilu Hospital of Shandong University and carried out with the ethical standards set forth in the Helsinki Declaration of 1975.
Data collection
Trained study team members collected demographic and clinical data by chart review. Demographic and microbiological data, predisposing factors, laboratory data, antifungal agent exposure and outcome were recorded on standardized case report forms. Underlying diseases, including solid organ tumor, hematologic malignancy, neutropenia, diabetes mellitus and chronic renal failure, were recorded. Predisposing factors that occurred within 30 days before the onset of candidemia were assessed. At the onset of candidemia (within two days following collection of the first positive blood sample), laboratory data were collected and the severity of the initial presentation of candidemia was assessed by APACHE II (20) and Sequential Organ Failure Assessment (SOFA) scores (21) . We recorded the antifungal agents used for more than two days within the window of two weeks before through two weeks after the microbiological documentation of candidemia infection.
During the study period, there was no change of policy in collecting Candida strains. Candida species were identified by use of the VITEK-32 system (BioMerieux Vitek, St. Louis, USA). Minimum Inhibitory Concentrations (MIC) of fluconazole, voriconazole, itraconazole and amphotericin B were determined using the ATB Fungus 3 microbroth method (BioMerieux, La Balme-les-Grottes, France). The procedure was performed according to the manufacturer's guidelines. All resistant isolates were confirmed using Etest (AB Biodisk, Solna, Sweden). We used the recently updated Clinical and Laboratory Standard Institute (CLSI) species-specific antifungal drug susceptibility thresholds for Candida after incubation at 35°C for 24 hours (22) (23) (24) (25) . Regarding fluconazole, isolates of C. albicans, C. tropicalis and C. parapsilosis with MICs of !eight μg/mL and isolates of C. glabrata with MICs of ! 64 μg/mL were considered resistant. Isolates of C. krusei were considered intrinsically resistant to fluconazole. For voriconazole, isolates of C. albicans, C. tropicalis and C. parapsilosis with MICs of !one μg/mL and C. krusei isolates with MICs of !two μg/ mL were considered resistant. Susceptibility results for itraconazole were categorized according to interpretive breakpoints recommended by the CLSI (25) . Since no breakpoints have been published by CLSI for amphotericin B, isolates inhibited by > two μg/mL were considered as resistant (26) .
Neutropenia was defined as an absolute neutrophil count <0.5×10 9 /L. Immunosuppressive drugs received included glucocorticoids (! 20 mg/day of prednisone or equivalent doses of other corticosteroids for more than one week), chemotherapy drugs or other immunosuppressive agents. Septic shock was defined as systolic blood pressure <90 mmHg, diastolic blood pressure <60 mmHg or if fluid/inotropes were required to maintain blood pressure above these levels (27) . Patients treated with adequate antifungal therapy were defined as those who met all of the following criteria: (i) antifungal agent with in vitro activity against the Candida species causing the infection; (ii) the administration of an antifungal agent with an adequate dosage according to the Infectious Diseases Society of America (IDSA) guidelines (28); e.g., the initial adequate dosage of fluconazole for susceptible isolates was defined as six mg/kg/day for C. albicans, C. tropicalis and C. parapsilosis in the face of normal renal function, and three mg/kg/day if creatinine clearance was <50 mL/min. Fluconazole was not considered to be adequate at any dosage for C. krusei or C. glabrata; (iii) antifungal administration for more than three days; (iv) administration of antifungal treatment within 72 hours after drawing the first positive blood sample for culture. 
Statistical analysis
The data for categorical variables were expressed as a percentage and continuous variables were expressed as the mean ± SD or the median (interquartile range). A Chisquare or Fisher's exact test (two-tailed) was used to compare categorical variables and unpaired Student's t test to compare continuous variables. The Kaplan-Meier analysis and log-rank test were used to compare day-90 survival. Multivariate, backwards, stepwise, logistic regression analyses were used to identify independent risk factors associated with day-90 mortality of patients with ICUAC and non-ICUAC; the results were presented as odds ratios (ORs) with 95% confidence intervals (95% CIs) and p values. Statistical analysis was performed using the SPSS 15.0 for Windows software package (SPSS, Chicago, USA). A p value of <0.05 was considered statistically significant.
Results
Patient demographics, epidemiology and risk factors for candidemia
A total of 275 cases were identified with Candidapositive blood cultures. Of these, 227 cases of candidemia in 227 patients were included in the analysis (Fig. 1) . Eighty candidemia cases were acquired in an ICU (ICUAC, 35.2%) and 147 cases were acquired in non-ICU settings (non-ICUAC, 64.8%), with an incidence of 15.1 cases/10,000 admissions and 1.65 cases/10,000 admissions, respectively. In both groups, C. albicans was the most commonly isolated species, followed by C. tropicalis and C. parapsilosis. The proportion of different Candida species and the resistance rate to antifungal agents did not differ between the ICUAC and non-ICUAC groups (all p>0.05, Table 1 ).
When compared with non-ICUAC patients, ICUAC patients had greater age, more often had underlying chronic renal insufficiency, more often received total parenteral nutrition, central venous catheter (CVC) or urethral catheter placement, and more often underwent respiratory failure supported with invasive mechanical ventilation and renal failure supported with renal replacement therapy (all p<0.05; Table 2 ). The incidence rates of solid tumor, hematological malignancy and neutropenia were greater for non-ICUAC than ICUAC cases (all p<0.05; Table 2 ).
Antifungal therapies, laboratory data and outcomes of patients
When compared to non-ICUAC patients, patients with ICUAC more often received echinocandins (28.8% vs. 6.1%; p<0.001) and less often received triazoles (67.5% vs. 81.0%; p=0.023). ICUAC patients also received more adequate antifungal therapy than non-ICUAC patients (47.5% vs. 38.8%; p=0.044; Table 3 ).
When compared with non-ICUAC patients, ICUAC patients had significantly lower platelet counts and higher levels of serum creatine, blood glucose and serum sodium and potassium, and a significantly higher APACHE II score (21.0±7.9 vs. 17.8±8.6; p=0.006) and SOFA score (9.2±5.5 vs. 7.4±3.9; p=0.010). ICUAC patients also displayed a significantly higher day-30 mortality rate (35.0% vs. 22.4%; p= 0.042) and day-90 mortality rate (52.5% vs. 36.7%; p= 0.022) and had significantly lower survival at 90 days (logrank test: p=0.016; Table 3 and Fig. 2 ).
Protective and risk factors for death in the two groups
Using a univariate analysis, the protective and risk factors for day-90 mortality with statistical significance were determined in the ICUAC and non-ICUAC groups (Table 4, 5) . Using a multivariate analysis, adequate antifungal therapy was found to be the only protective factor for death in both the ICUAC and non-ICUAC groups (OR 0.5 with 95% CI 
Discussion
In this study, a higher incidence of candidemia was observed in ICU than in non-ICU settings. However, the distribution of Candida species and the resistance to antifungal agents were similar between the ICUAC and non-ICUAC groups. The administration of adequate antifungal therapy was found to be the only protective factor for death in both groups. ICUAC patients with severe organ failure needed supportive implementation, while non-ICUAC patients with advanced age and concurrent bacteremia had significantly higher risk for death. The predictors of death may be relevant for the clinical management of patients with candidemia in ICU and non-ICU settings.
The different Candida species may vary in their susceptibility to various antifungal agents (29) . Thus, a better understanding of the epidemiology of candidemia in the ICU and other hospital settings is important for clinicians to implement prophylactic or empirical therapy. According to recent studies, the distribution of Candida species differs by hospital units. C. albicans dominates in hemato-oncology units while non-albicans Candida occurs frequently in General Surgery units and in ICUs (30) . Similarly, the incidence rate of C. tropicalis and C. krusei infection differs between internal medicine wards, surgical wards and ICU wards (31) . In this study, however, the distribution of Candida species and resistance to antifungal agents were similar between ICU and non-ICU settings. The same results were reported by the SENTRY Antimicrobial Surveillance Program (32) . Therefore, for ICU physicians, local pathogen characteristics in non-ICU settings can also be referenced when choosing antifungal agents.
We identified several healthcare-related factors associated with ICUAC, including multiple blood product transfusion, mechanical ventilation and CVC and urethral catheter placement, suggesting that candidemia might be preventable by a reduction in unnecessary medical procedures whenever feasible in ICU settings. In a previous report (33) , removal of a CVC was associated with decreased mortality. Considering that CVC placement is more common in patients with ICUAC than in patients with non-ICUAC, the management and early removal of an unnecessary CVC requires more attention in the ICU. The CVC removal rate in this study was only 48.3% (data not shown), indicating that the awareness of the risk of CVC retention needs to be strengthened in the management of candidemia. In addition, although candidemia is associated with high mortality, reported mortality rates range from 38 to 85% among studies that included different patient populations (34) (35) (36) . In this study, it is not surprising that ICUAC patients had poorer outcomes when compared to non-ICUAC patients, since they were much more severe, as reflected by a higher incidence of septic shock and higher APACHE II and SOFA scores.
A delay in the initiation of antifungal therapy in hospitalized patients with candidemia has been shown to significantly impact mortality (37) . In this study, delayed therapy was included as a component of inadequate antifungal therapy, which occurs commonly and results in substantial prolongation of the hospital length of stay and increased hospital costs (38) . Efforts to enhance the rates of appropriate therapy for candidemia may improve resource use. Adequate treatment was associated with reduced mortality (39) , and was found to be the only protective factor in both groups of this study, indicating that standard antifungal therapies administered according to accepted guidelines should be encouraged in both the ICU and non-ICU settings. In this study, the rate of "adequate antifungal therapy" was quite low (41.9%) and the main reason for this finding might be related to the lack of knowledge with regard to the IDSA guidelines of candidemia treatment (28) among the physicians in the participating hospitals.
The different predictors of death may be relevant for differential clinical management of patients with candidemia in ICU and non-ICU settings. Severe organ failure is the main cause of death in ICU patients, and even patients receiving organ supportive implementation are still at high risk of death (40, 41) . In this study, the predictors of death in ICUAC patients included several organ supportive implementations, indicating early correction of organ failure and removal of these supportive implementations might improve the prognosis of ICU patients with candidemia. Interestingly, these supportive implementations were not predictors of death in non-ICUAC patients. Instead, the underlying host conditions, including advanced age and concurrent bacteremia, were found to be predictive for death in non-ICUAC patients, highlighting that prompt initiation of adequate antifungal therapy is especially important in the candidemic pa- The APACHE II scoring system, which is widely used as a measure of the severity of illness and a predictor for death in ICU settings (20) , is not often used in non-ICU settings. However, for the patients with candidemia, a higher APACHE II score was identified as an independent risk factor for death (33, 37) . Our study highlights the prognostic significance of APACHE II in patients with candidemia in both ICU and non-ICU settings, indicating that the APACHE II score is a useful tool for the prediction of death in patients with candidemia admitted to non-ICU departments.
There are several limitations associated with our study. First, this study is an analysis of retrospectively gathered data, and may be subject to the limitations of the retrospective cohort design. Second, we did not further confirm the species of the strains genetically by deoxyribonucleic acid sequencing, which is reported to be more accurate than the VITEK-32 system used in this study. However, the results obtained using the VITEK-32 system that showed poor discrimination or non-identification at the level of species were not included, which would further elevate the accuracy of the system as applied to this study. Third, we did not collect data on the exact time between candidemic episodes and the initiation of antifungal therapy, which, in addition to the sample size, precluded further analysis of the effect of the time difference on the clinical outcome. Fourth, we were not able to evaluate the long-term prognosis (including 6-month or 1-year outcomes) due to the high incidence of loss to follow-up. Therefore, we were limited to day-90 mortality as the mortality outcome in this study.
In conclusion, the Candida species and antifungal resistance profiles in patients with ICUAC were similar to those of non-ICUAC patients, but led to worse outcomes. In both groups, higher APACHE II scores were shown to be a common predictor of death, and adequate antifungal therapy should be encouraged in order to decrease mortality. Additional predictors of death that were differentially associated with the ICUAC and non-ICUAC patient groups may be relevant for the clinical management of patients with can-didemia in ICU and non-ICU settings.
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